338840 — Y Biologics Cashflow Statement
0.000.00%
Last trade - 00:00- KR₩365bn
- KR₩342bn
- KR₩6bn
Annual cashflow statement for Y Biologics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
| Standards: | — | — | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -17,071 | -18,804 | -20,871 | -6,442 |
| Depreciation | ||||
| Amortisation | ||||
| Non-Cash Items | 1,223 | 3,469 | 12,597 | -334 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 4,364 | 2,269 | -1,688 | 595 |
| Change in Accounts Receivable | ||||
| Change in Prepaid Expenses | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Payable / Accrued Expenses | ||||
| Change in Taxes Payable | ||||
| Change in Other Liabilities | ||||
| Other Operating Cash Flow | ||||
| Cash from Operating Activities | -9,168 | -10,105 | -7,607 | -4,143 |
| Capital Expenditures | -7,571 | -1,097 | -196 | -2,860 |
| Purchase of Fixed Assets | ||||
| Purchase / Acquisition of Intangibles | ||||
| Other Investing Cash Flow Items | -325 | 338 | 3,911 | -2,562 |
| Sale of Fixed Assets | ||||
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | -7,896 | -759 | 3,715 | -5,422 |
| Financing Cash Flow Items | — | — | — | 65 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 248 | 6,896 | 11,782 | -1,928 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | -16,516 | -4,259 | 7,922 | -11,452 |